Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM.
Tarhini AA, et al. Among authors: laframboise wa.
J Immunother Cancer. 2022 Jan;10(1):e004310. doi: 10.1136/jitc-2021-004310.
J Immunother Cancer. 2022.
PMID: 35074904
Free PMC article.
Clinical Trial.